Levocloperastine is a novel antitussive with a pharmacological profile distinct from that of the racemic DL-cloperastine. Levocloperastine with its dual mechanism of action acts on both the ...

Volume of distribution at steady state (L/kg) 187 194 194 Table 2. Changes in cough-related symptoms following treatment with levocloperastine 30, 60 and 120 mg/day for 6 days in patients with ...

There is a large unmet medical need in novel antitussive drugs as current standard-of-care are ineffective in 30% of patients or only moderately effective in up to 60% of patients. In addition ...

WATERTOWN, Mass., November 18, 2024--(BUSINESS WIRE)--Nocion Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel small molecule charged sodium channel blockers called ...